Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $11.2 million.

  • CorMedix's Cost of Revenue rose 6574.62% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.3 million, marking a year-over-year increase of 2354.62%. This contributed to the annual value of $28.7 million for FY2024, which is 5863.16% up from last year.
  • According to the latest figures from Q3 2025, CorMedix's Cost of Revenue is $11.2 million, which was up 6574.62% from $6.4 million recorded in Q2 2025.
  • CorMedix's 5-year Cost of Revenue high stood at $11.2 million for Q3 2025, and its period low was $332.0 during Q2 2022.
  • In the last 5 years, CorMedix's Cost of Revenue had a median value of $3.3 million in 2023 and averaged $3.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 9915.43% in 2022, then skyrocketed by 98063704.82% in 2023.
  • Quarter analysis of 5 years shows CorMedix's Cost of Revenue stood at $48007.0 in 2021, then plummeted by 99.15% to $406.0 in 2022, then skyrocketed by 999512.81% to $4.1 million in 2023, then skyrocketed by 103.62% to $8.3 million in 2024, then skyrocketed by 35.36% to $11.2 million in 2025.
  • Its Cost of Revenue stands at $11.2 million for Q3 2025, versus $6.4 million for Q2 2025 and $4.5 million for Q1 2025.